Giordano, G.; Parcesepe, P.; Bruno, G.; Piscazzi, A.; Lizzi, V.; Remo, A.; Pancione, M.; D’Andrea, M.R.; De Santis, E.; Coppola, L.;
et al. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int. J. Mol. Sci. 2021, 22, 7717.
https://doi.org/10.3390/ijms22147717
AMA Style
Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D’Andrea MR, De Santis E, Coppola L,
et al. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. International Journal of Molecular Sciences. 2021; 22(14):7717.
https://doi.org/10.3390/ijms22147717
Chicago/Turabian Style
Giordano, Guido, Pietro Parcesepe, Giuseppina Bruno, Annamaria Piscazzi, Vincenzo Lizzi, Andrea Remo, Massimo Pancione, Mario Rosario D’Andrea, Elena De Santis, Luigi Coppola,
and et al. 2021. "Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era" International Journal of Molecular Sciences 22, no. 14: 7717.
https://doi.org/10.3390/ijms22147717
APA Style
Giordano, G., Parcesepe, P., Bruno, G., Piscazzi, A., Lizzi, V., Remo, A., Pancione, M., D’Andrea, M. R., De Santis, E., Coppola, L., Pietrafesa, M., Fersini, A., Ambrosi, A., & Landriscina, M.
(2021). Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. International Journal of Molecular Sciences, 22(14), 7717.
https://doi.org/10.3390/ijms22147717
